242 related articles for article (PubMed ID: 34358567)
1. Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!
Guarino M; Cossiga V; Esposito I; Furno A; Morisco F
J Hepatol; 2022 Jan; 76(1):237-239. PubMed ID: 34358567
[No Abstract] [Full Text] [Related]
2. Reply to: "Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!".
Rabinowich L; Shibolet O; Katchman H
J Hepatol; 2022 Jan; 76(1):239-240. PubMed ID: 34634386
[No Abstract] [Full Text] [Related]
3. COVID-19 vaccination immune paresis in heart and lung transplantation.
Aslam S; Danziger-Isakov L; Mehra MR
J Heart Lung Transplant; 2021 Aug; 40(8):763-766. PubMed ID: 34144891
[No Abstract] [Full Text] [Related]
4. Acceptance of SARS-CoV-2 vaccines by liver transplant recipients and candidates.
Reuken PA; Albers S; Rauchfuss F; Strnad P; Settmacher U; Trautwein C; Stallmach A; Bruns T
Z Gastroenterol; 2021 Dec; 59(12):1288-1296. PubMed ID: 34670294
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
6. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
Cornberg M; Buti M; Eberhardt CS; Grossi PA; Shouval D
J Hepatol; 2021 Apr; 74(4):944-951. PubMed ID: 33563499
[TBL] [Abstract][Full Text] [Related]
7. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
8. Antibody response to SARS-CoV-2 vaccination, previous SARS-CoV-2 infection, and change to single-dose vaccination.
Mungmunpuntipantip R; Wiwanitkit V
J Med Virol; 2021 Dec; 93(12):6474. PubMed ID: 34374991
[No Abstract] [Full Text] [Related]
9. [Rapid guideline for COVID-19 vaccination in patients with chronic liver diseases, hepatolbiliary malignancy and liver transplant].
Chinese Society of Hepatology, Chinese Medical Association
Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):523-526. PubMed ID: 34192840
[No Abstract] [Full Text] [Related]
10. SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021.
Griffin JB; Haddix M; Danza P; Fisher R; Koo TH; Traub E; Gounder P; Jarashow C; Balter S
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1170-1176. PubMed ID: 34437525
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 infection long time after full vaccination is related to a lack of neutralizing antibodies.
Alidjinou EK; Gaillot O; Guigon A; Tinez C; Lazrek M; Bocket L; Engelmann I; Hober D
Diagn Microbiol Infect Dis; 2022 Jan; 102(1):115565. PubMed ID: 34731684
[TBL] [Abstract][Full Text] [Related]
12. High acceptance rate of COVID-19 vaccination in liver transplant recipients.
Giannini EG; Marenco S
J Hepatol; 2021 Aug; 75(2):483-484. PubMed ID: 34052253
[No Abstract] [Full Text] [Related]
13. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.
Li XN; Huang Y; Wang W; Jing QL; Zhang CH; Qin PZ; Guan WJ; Gan L; Li YL; Liu WH; Dong H; Miao YT; Fan SJ; Zhang ZB; Zhang DM; Zhong NS
Emerg Microbes Infect; 2021 Dec; 10(1):1751-1759. PubMed ID: 34396940
[TBL] [Abstract][Full Text] [Related]
14. Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab.
Khayat-Khoei M; Conway S; Rubinson DA; Jarolim P; Houtchens MK
J Neurol; 2021 Oct; 268(10):3592-3594. PubMed ID: 33638680
[No Abstract] [Full Text] [Related]
15. Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role?
Broccolo F
Clin Chem Lab Med; 2022 Feb; 60(3):64-65. PubMed ID: 35026883
[No Abstract] [Full Text] [Related]
16. An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021.
Williams SV; Vusirikala A; Ladhani SN; Fernandez Ruiz De Olano E; Iyanger N; Aiano F; Stoker K; Gopal Rao G; John L; Patel B; Andrews N; Dabrera G; Ramsay M; Brown KE; Lopez Bernal J; Saliba V
Euro Surveill; 2021 Jul; 26(27):. PubMed ID: 34240699
[TBL] [Abstract][Full Text] [Related]
17. HCV detection is possible during SARS CoV-2 testing; and throughout COVID-19 vaccination?
Crespo J; Díaz-González Á; Cabezas J
J Hepatol; 2021 Aug; 75(2):486-487. PubMed ID: 33971225
[No Abstract] [Full Text] [Related]
18. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
19. Cluster analysis reveals three main patterns of beliefs and intention with respect to SARS-CoV-2 vaccination in patients with autoimmune and inflammatory diseases.
Felten R; Dubois M; Ugarte-Gil MF; Chaudier A; Kawka L; Bergier H; Costecalde C; Pijnenburg L; Fort J; Chatelus E; Sordet C; Javier RM; Gottenberg JE; Sibilia J; Fuentes-Silva YJ; Arnaud L
Rheumatology (Oxford); 2021 Oct; 60(SI):SI68-SI76. PubMed ID: 33983432
[TBL] [Abstract][Full Text] [Related]
20. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
